T1	DISO 87 104	migraña episódica
#1	AnnotatorNotes T1	C4760993; Episodic migraine; Disease or Syndrome
T2	PROC 127 195	Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo
T3	CHEM 217 226	LY2951742
#2	AnnotatorNotes T3	C4742733; LY2951742; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	PROC 73 83	prevención
#3	AnnotatorNotes T4	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T5	DISO 244 261	migraña episódica
#4	AnnotatorNotes T5	C4760993; Episodic migraine; Disease or Syndrome
T6	DISO 304 311	Migraña
#5	AnnotatorNotes T6	C0149931; Migraine Disorders; Disease or Syndrome
T7	DISO 338 355	Migraña episódica
#6	AnnotatorNotes T7	C4760993; Episodic migraine; Disease or Syndrome
T8	PROC 465 478	diagnosticado
#7	AnnotatorNotes T8	C0011900; Diagnosis; Diagnostic Procedure
T9	DISO 479 486	migraña
#8	AnnotatorNotes T9	C0149931; Migraine Disorders; Disease or Syndrome
T10	DISO 739 747	migrañas
#9	AnnotatorNotes T10	C0149931; Migraine Disorders; Disease or Syndrome
T11	PROC 850 864	ensayo clínico
#10	AnnotatorNotes T11	C0008976; Clinical Trials; Research Activity
T12	CHEM 1108 1117	LY2951742
#11	AnnotatorNotes T12	C4742733; LY2951742; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	CHEM 1125 1135	anticuerpo
#12	AnnotatorNotes T13	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T14	CHEM 1194 1202	fármacos
#13	AnnotatorNotes T14	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T15	PROC 1205 1217	tratamientos
#14	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	PROC 1223 1231	prevenir
#15	AnnotatorNotes T16	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T17	DISO 1236 1244	migrañas
#16	AnnotatorNotes T17	C0149931; Migraine Disorders; Disease or Syndrome
T18	DISO 1245 1262	Hipersensibilidad
#17	AnnotatorNotes T18	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T19	CHEM 1274 1282	fármacos
#18	AnnotatorNotes T19	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T20	CHEM 1284 1308	anticuerpos monoclonales
#19	AnnotatorNotes T20	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T21	CHEM 1146 1150	CGRP
#20	AnnotatorNotes T21	C0006669; Calcitonin Gene-Related Peptide; Amino Acid, Peptide, or Protein · Hormone
T22	DISO 1460 1503	migraña hemipléjica (esporádica o familiar)
#21	AnnotatorNotes T22	C0338484; Familial Hemiplegic Migraine; Disease or Syndrome + C1832903; MIGRAINE, SPORADIC HEMIPLEGIC; Disease or Syndrome
T23	DISO 1396 1403	cefalea
#22	AnnotatorNotes T23	C0018681; Headache; Sign or Symptom
T24	DISO 1405 1423	cefalea en racimos
#23	AnnotatorNotes T24	C0009088; Cluster Headache; Disease or Syndrome
T25	DISO 1438 1445	migraña
#24	AnnotatorNotes T25	C0149931; Migraine Disorders; Disease or Syndrome
T26	DISO 1508 1530	migraña oftalmopléjica
#25	AnnotatorNotes T26	C0221058; Ophthalmoplegic Migraine; Disease or Syndrome
T27	DISO 1536 1552	migraña con aura
#26	AnnotatorNotes T27	C0154723; Migraine with Aura; Disease or Syndrome
T28	DISO 1573 1588	migraña basilar
#27	AnnotatorNotes T28	C0270860; Basilar-Type Migraine; Disease or Syndrome
T29	ANAT 1557 1571	troncoencéfalo
#28	AnnotatorNotes T29	C1306665; Entire brainstem; Body Part, Organ, or Organ Component
T30	CHEM 60 69	LY2951742
#29	AnnotatorNotes T30	C4742733; LY2951742; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T31	DISO 666 674	migrañas
#30	AnnotatorNotes T31	C0149931; Migraine Disorders; Disease or Syndrome
T32	CHEM 1345 1354	LY2951742
#31	AnnotatorNotes T32	C4742733; LY2951742; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T33	CHEM 1317 1339	proteínas terapéuticas
#32	AnnotatorNotes T33	C0872285; therapeutic protein; Pharmacologic Substance
T34	ANAT 1581 1588	basilar
#33	AnnotatorNotes T34	C0004811; Structure of basilar artery; Body Part, Organ, or Organ Component
T35	Date 13 17	2015
T36	LIVB 230 239	pacientes
#34	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	LIVB 382 391	Pacientes
#35	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	Age 395 405	18-65 años
T39	Duration 675 698	al menos durante el año
T40	Age 761 768	50 años
T41	Date 815 831	en la actualidad
T44	Frequency 1384 1391	diarios
T42	CHEM 892 925	producto en fase de investigación
#36	AnnotatorNotes T42	C0013230; Investigational New Drugs; Pharmacologic Substance
T43	PROC 954 974	investigación médica
#37	AnnotatorNotes T43	C0079816; Medical Research activity; Research Activity
T45	Quantifier_or_Qualifier 718 719	1
T46	PROC 711 717	visita
#39	AnnotatorNotes T46	C1512346; Patient Visit; Health Care Activity
A1	Status T31 History_of
A2	Status T12 History_of
A3	Status T13 History_of
A4	Status T18 History_of
A5	Status T23 History_of
A6	Status T24 History_of
A7	Status T25 History_of
A8	Status T22 History_of
A9	Status T26 History_of
A10	Status T27 History_of
A11	Status T28 History_of
#40	AnnotatorNotes T2	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#41	AnnotatorNotes T41	C0521116; Current (present time); Temporal Concept 
T47	Neg_cue 996 998	no
T48	Observation 1002 1027	compatible con el estudio
A12	Assertion T48 Negated
#38	AnnotatorNotes T48	C1302261; Patient eligible for clinical trial; Finding (?)
R1	Used_for Arg1:T30 Arg2:T4	
R2	Before Arg1:T4 Arg2:T1	
R3	Experiences Arg1:T36 Arg2:T3	
R4	Experiences Arg1:T36 Arg2:T5	
R5	Has_Age Arg1:T37 Arg2:T38	
T49	PROC 444 453	selección
#42	AnnotatorNotes T49	C0242802; Patient Selection; Research Activity
R6	Overlap Arg1:T49 Arg2:T38	
T50	CONC 507 644	directrices de la International Classification of Headache Disorders (ICHD)-3 beta (1.1 o 1.2) de la International Headache Society (IHS)
R7	Used_for Arg1:T50 Arg2:T8	
R8	Has_Duration_or_Interval Arg1:T31 Arg2:T39	
R9	Before Arg1:T31 Arg2:T46	
R10	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T45	
R11	Before Arg1:T10 Arg2:T40	
R12	Has_Duration_or_Interval Arg1:T9 Arg2:T39	
R13	Before Arg1:T9 Arg2:T46	
R14	Before Arg1:T9 Arg2:T40	
R15	Before Arg1:T31 Arg2:T40	
R16	Before Arg1:T10 Arg2:T46	
T51	Observation 802 814;832 864	participando en cualquier otro ensayo clínico
R17	Overlap Arg1:T51 Arg2:T41	
T52	Observation 802 814;928 974	participando en cualquier otro tipo de investigación médica
R19	Negation Arg1:T47 Arg2:T48	
R20	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T48	
R21	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T48	
T53	Quantifier_or_Qualifier 1136 1150	frente al CGRP
R22	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T53	
A13	Status T53 History_of
T54	Quantifier_or_Qualifier 1177 1187	simultánea
#43	AnnotatorNotes T54	C0521115; Simultaneous; Temporal Concept
R23	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T54	
R24	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T54	
R25	Before Arg1:T16 Arg2:T17	
R26	Used_for Arg1:T14 Arg2:T16	
R27	Used_for Arg1:T15 Arg2:T16	
R28	Causes Arg1:T19 Arg2:T18	
R29	Causes Arg1:T20 Arg2:T18	
R30	Causes Arg1:T33 Arg2:T18	
R31	Causes Arg1:T32 Arg2:T18	
T55	Quantifier_or_Qualifier 1369 1381	persistentes
#44	AnnotatorNotes T55	C0205322; Persistent; Temporal Concept
R32	Has_Frequency Arg1:T23 Arg2:T44	
R33	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T55	
R34	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T55	
R35	Has_Frequency Arg1:T24 Arg2:T44	
R36	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T55	
R37	Has_Frequency Arg1:T25 Arg2:T44	
R38	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T55	
R39	Has_Frequency Arg1:T22 Arg2:T44	
R40	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T55	
R41	Has_Frequency Arg1:T26 Arg2:T44	
R42	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T55	
R43	Has_Frequency Arg1:T27 Arg2:T44	
R44	Location_of Arg1:T29 Arg2:T27	
R45	Location_of Arg1:T34 Arg2:T28	
R46	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T55	
R47	Has_Frequency Arg1:T28 Arg2:T44	
T56	CONC 1610 1641	criterios ICHD-3 beta de la IHS
R48	Has_Duration_or_Interval Arg1:T10 Arg2:T39	
#45	AnnotatorNotes T45	C0205447; One; Quantitative Concept
A14	Experiencer T36 Patient
A15	Experiencer T37 Patient
